This assumption is also supported by our finding of increased LARGE1 level in CSF of SMA patients compared to controls characterized by a further LARGE1-increase in pediatric and adult cases under nusinersen therapy. This evidence concerns the gene LARGE1 and proximal spinal muscular atrophy.